Amyloidosis Tx Scores; 'Natriuretic Peptide Deficiency'; Statin During Chemo
email article Novel RNAi drug vutrisiran met its primary endpoint in topline results from the phase III HELIOS-A trial in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy and improved the exploratory cardiac biomarker endpoint as well, Alnylam Pharmaceuticals announced. Mental health disorders among heart attack patients have increased in the last decade, researchers warned in the American Journal of Preventive Cardiology. "Natriuretic peptide deficiency" m...
United States Firstword Medtech Alnylam Pharmaceuticals American Heart Association American College Of Cardiology American Medical Society For Sports Medicine
Source: medpagetoday.com